Phase III trial of loxapine [Adasuve] in adolescent patients with agitation

Trial Profile

Phase III trial of loxapine [Adasuve] in adolescent patients with agitation

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2015

At a glance

  • Drugs Loxapine (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jun 2015 New trial record
    • 18 Jun 2015 According to a media release, Alexza Pharmaceuticals plans to transfer the EU Marketing authorization for ADASUVE (MAA) to Ferrer. The MAA transfer includes the responsibilities for the ongoing post-approval clinical studies (the PASS and DUS studies), a planned phase III trial in adolescents and ongoing pharmacovigilance responsibilities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top